Publicacións nas que colabora con Luis Bujanda Fernández de Piérola (21)

2023

  1. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)

    PLoS Medicine, Vol. 20, Núm. 10

2020

  1. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort

    Molecular Biology Reports, Vol. 47, Núm. 3, pp. 1583-1588

  2. Predictive value of carcinoembryonic antigen in symptomatic patients without colorectal cancer: A post-hoc analysis within the colonpredict cohort

    Diagnostics, Vol. 10, Núm. 12

2019

  1. Correction: Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer (Clinical and Translational Gastroenterology, (2019) 10, e-00031, 10.14309/ctg.0000000000000003)

    Clinical and Translational Gastroenterology

  2. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer

    Clinical and translational gastroenterology, Vol. 10, Núm. 1, pp. e00003

2017

  1. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs

    United European Gastroenterology Journal, Vol. 5, Núm. 2, pp. 255-260

2016

  1. The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer

    European Journal of Human Genetics, Vol. 24, Núm. 10, pp. 1501-1505

2015

  1. Diagnostic Performance of Fecal Immunochemical Test and Sigmoidoscopy for Advanced Right-Sided Colorectal Neoplasms

    Digestive Diseases and Sciences, Vol. 60, Núm. 5, pp. 1424-1432

  2. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer

    Journal of Medical Genetics, Vol. 52, Núm. 7, pp. 498-502

2014

  1. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer

    Human Genetics, Vol. 133, Núm. 5, pp. 525-534

  2. Characteristics of adenomas detected by fecal immunochemical test in colorectal cancer screening

    Cancer Epidemiology Biomarkers and Prevention, Vol. 23, Núm. 9, pp. 1884-1892

  3. Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening

    United European Gastroenterology Journal, Vol. 2, Núm. 6, pp. 522-529

  4. Fecal immunochemical test accuracy in average-risk colorectal cancer screening

    World Journal of Gastroenterology, Vol. 20, Núm. 4, pp. 1038-1047

  5. Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests

    Clinical Gastroenterology and Hepatology, Vol. 12, Núm. 10, pp. 1708-1716.e4

2013

  1. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12

    BMC Genomics, Vol. 14, Núm. 1

  2. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern european populations

    Carcinogenesis, Vol. 34, Núm. 2, pp. 314-318

  3. Corrigendum

    Carcinogenesis

  4. Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

    Pharmacogenomics Journal, Vol. 13, Núm. 3, pp. 209-217

  5. Risk of cancer in cases of suspected lynch syndrome without germline mutation

    Gastroenterology, Vol. 144, Núm. 5

2012

  1. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening

    New England Journal of Medicine, Vol. 366, Núm. 8, pp. 697-706